American Society of Hematology

SHERPA: Blue

People

  1. Zelenetz
    Zelenetz
  2. Hamlin
    Hamlin
  3. Kumar
    Kumar
  4. Horwitz
    Horwitz
  5. Moskowitz
    Moskowitz
  6. Noy
    Noy
  7. Palomba
    Palomba
  8. Seshan
    Seshan
  9. Caron
    Caron
  10. Drullinsky
    Drullinsky

Groups

  1. Center for Hematologic Malignancies (10)
  2. Department of Medicine (10)
  3. Executive Committee, Center for Hematologic Malignancies (10)
  4. Hematologic Malignancies, Division of (10)
  5. Lymphoma (10)
  6. Biostatistics Service (7)
  7. Epidemiology and Biostatistics (7)
  8. Nursing (5)
  9. Sloan Kettering Institute Postdocs (5)
  10. Bone Marrow Transplant (4)
Search Within
  1. "2016"
  2. "Anas Younes"
Formats
  1. Meeting Abstract (7)
  2. Journal Article (3)
Groups
  1. Center for Hematologic Malignancies (10)
  2. Department of Medicine (10)
  3. Executive Committee, Center for Hematologic Malignancies (10)
  4. Hematologic Malignancies, Division of (10)
  5. Lymphoma (10)
  6. Biostatistics Service (7)

More Groups

People
  1. Anas Younes (10)
  2. Andrew Zelenetz (6)
  3. Anita Kumar (5)
  4. Paul Hamlin (5)
  5. Alison Moskowitz (4)
  6. Ariela Noy (4)

More People

Years
  1. 2016 (10)
Publications
  1. Blood (10)

Results (10)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Dual inhibition of histone deacetylases and phosphoinositide 3-kinase enhances therapeutic activity against B cell lymphoma
    Meeting Abstract

    Mondello, P.; Derenzini, E.; Asgari, Z.; Philip, J.; Brea, E. J.; Seshan, V. E.; Hendrickson, R.; de Stanchina, E.; Scheinberg, D. A.; Younes, A.
    Blood (2016)

    Fulltext@MSK | Save
  • MYC-dependent PI3K and MCL-1 feedbacks attenuate BET inhibitors activity in diffuse large B-cell lymphoma
    Meeting Abstract

    Derenzini, E.; Mondello, P.; Liu, Y.; Scallion, M.; Asgari, Z.; Philip, J.; Hilden, P.; Djaballah, H.; Ouerfelli, O.; de Stanchina, E.; more...
    Blood (2016)

    Fulltext@MSK | Save
  • A Phase Ib/IIa trial of the combination of romidepsin, lenalidomide and carfilzomib in patients with relapsed/refractory lymphoma shows complete responses in relapsed and refractory T-cell lymphomas
    Meeting Abstract

    Mehta-Shah, N.; Moskowitz, A. J.; Lunning, M.; Lynch, P.; Scheuerman, M.; Kumar, A.; Gerecitano, J. F.; Zelenetz, A. D.; Hamlin, P. A. Jr; Noy, A.; more...
    Blood (2016)

    Fulltext@MSK | Save
  • Outcome of initial observation in mantle cell lymphoma
    Meeting Abstract

    Kumar, A.; Ying, Z.; Alperovich, A.; Dogan, A.; Hamlin, P. A. Jr; Moskowitz, C. H.; Portlock, C. S.; Zelenetz, A. D.; Zhang, Z.; Woo, K. M.; more...
    Blood (2016)

    Fulltext@MSK | Save
  • The final report of a phase I/II study of panobinostat in combination with ICE (ifosfamide, carboplatin and etoposide) in patients (pts) with relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL)
    Meeting Abstract

    Hu, B.; Younes, A.; Claret, L.; Feng, L.; Westin, J. R.; Fowler, N.; Neelapu, S.; Hagemeister, F. B.; Rodriguez, M. A.; Samaniego, F.; more...
    Blood (2016)

    Fulltext@MSK | Save
  • Outcomes of follicular lymphoma patients by dynamic FLIPI at diagnosis and initial treatment in the post-rituximab era
    Meeting Abstract

    Batlevi, C.; Alperovich, A.; Smith, K.; Ying, Z.; Soumerai, J. D.; Copeland, A. R.; Joffe, E.; Caron, P.; Drullinsky, P.; Gerecitano, J. F.; more...
    Blood (2016)

    Fulltext@MSK | Save
  • Benchmark of progression free survival for multiple lines of therapy in follicular lymphoma treated in the rituximab era
    Meeting Abstract

    Alperovich, A.; Batlevi, C.; Smith, K.; Ying, Z.; Soumerai, J. D.; Copeland, A. R.; Joffe, E.; Caron, P.; Drullinsky, P.; Gerecitano, J. F.; more...
    Blood (2016)

    Fulltext@MSK | Save
  • Integrated genomic DNA/RNA profiling of hematologic malignancies in the clinical setting
    Journal Article

    He, J.; Abdel-Wahab, O.; Nahas, M. K.; Wang, K.; Rampal, R. K.; Intlekofer, A. M.; Patel, J.; Krivtsov , A.; Frampton, G. M.; Young, L. E.; more...
    Blood (2016)

    Fulltext@MSK | Save
  • Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma
    Journal Article

    Chen, R.; Gopal, A. K.; Smith, S. E.; Ansell, S. M.; Rosenblatt, J. D.; Savage, K. J.; Connors, J. M.; Engert, A.; Larsen, E. K.; Huebner, D.; more...
    Blood (2016)

    Fulltext@MSK | Save
  • Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma
    Journal Article

    Kumar, A.; Casulo, C.; Yahalom, J.; Schòˆder, H.; Barr, P. M.; Caron, P.; Chiu, A.; Constine, L. S.; Drullinsky, P.; Friedberg, J. W.; more...
    Blood (2016)

    Fulltext@MSK | Save